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background: The 2014 AHA/ACC/HRS guidelines for management of patients (pts) with atrial fibrillation (AF) recommend the CHA2DS2-
VASc score over the CHADS2 score for stroke risk assessment. We compared the change in the number of pts requiring anticoagulation 
(AC) for stroke prevention based on the CHA2DS2-VASc scoring system and assessed practice patterns in our institution.
Methods: We conducted a chart review of pts (age ≥18) discharged with a diagnosis of non-valvular AF from June 2013-2014. CHADS2 
and CHA2DS2-VASc scores were computed and the choice of an oral AC regimen on admission and discharge was recorded. A 
CHA2DS2-VASc score ≥ 2 was considered an indication for AC.
Results: 812 patient charts were reviewed. An overall 20.3% increase was seen in pts (789 vs. 656) requiring AC for stroke prevention. 
CHA2DS2-VASc scores were significantly higher than CHADS2 scores in both women (5.2±1.72 vs. 3.3±1.62; p<0.001) and men (4.3±1.92 
vs. 3.0±1.63; p<0.001). Using CHA2DS2-VASc scores significantly increased the number of males needing AC (24.4%, 448 vs. 360), 
compared to females (15.2%, 341 vs. 296) with p< 0.02. Using CHA2DS2-VASc, 608/789 pts (77.1%) were admitted and 707/789 (89.6%) 
were discharged on proper AC (p<0.001). Out of 608 pts admitted with non-valvular AF, warfarin (77.6%), rivaroxaban (12.0%), dabigatran 
(8.1%), apixaban (1.3%) and other AC (0.1%) were used. On discharge, 707 pts were treated with AC using warfarin (67.7%), rivaroxaban 
(20.5%), dabigatran (5.0%), apixaban (4.1%) and other AC (2.7%).
conclusion: We found a significant increase in the number of pts requiring AC using CHA2DS2-VASc compared to CHADS2. CHA2DS2-
VASc scoring was more likely to increase the need for AC in men than women. The significantly increased use of appropriate AC on 
discharge is consistent with increased adoption of CHA2DS2-VASc in our non-European institution. The majority of AC pts were treated 
with warfarin. Among novel oral anticoagulants, rivaroxaban was prescribed most frequently suggesting a bias toward once a day dosing, 
though apixaban was on our formulary for only 6 months. Further comparisons of strokes and adverse events on different AC are needed 
to clarify their benefit-risk ratios in AF pts.
